AIM
AIM
AMEX · Biotechnology

Aim Immunotech Inc

$0.96
+0.04 (+4.46%)
As of Mar 22, 11:03 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.66M
Net Income
-168,962,176
Gross Margin
81.8%
Profit Margin
-10,188.2%
Rev Growth
+8.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 81.8% 81.8% 50.8% 50.8%
Operating Margin -11,630.6% -10,467.5% -19.6% -21.6%
Profit Margin -10,188.2% -9,678.8% -22.2% -17.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.66M 1.54M 1.31M 1.61M
Gross Profit 1.36M 1.26M 667.2K 816.8K
Operating Income -192,895,312 -160,760,978 -257,805 -347,025
Net Income -168,962,176 -140,814,851 -292,011 -275,194
Gross Margin 81.8% 81.8% 50.8% 50.8%
Operating Margin -11,630.6% -10,467.5% -19.6% -21.6%
Profit Margin -10,188.2% -9,678.8% -22.2% -17.1%
Rev Growth +8.0% +8.0% +20.5% -9.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.16M 1.06M
Total Equity 1.39M 1.56M
D/E Ratio 0.83 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -208,168,754 -183,128,360 -341,169 -390,753
Free Cash Flow -173,511 -203,411